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Hospital Outcomes Among COVID-19 Hospitalizations
With Myocarditis from the California State Inpatient
Database
Muni Rubens, MD, PhDa, Venkataraghavan Ramamoorthy, MD, PhDb, Anshul Saxena, BDS, PhDb,
Juan Carlos Zevallos, MDc,d, Juan Gabriel Ruiz-Pelaez, MDe, Md Ashfaq Ahmed, PhDb,
Zhenwei Zhang, PhDb, Peter McGranaghan, PhDf, Emir Veledar, PhDb, Javier Jimenez, MD, PhDc,e, and
Sandra Chaparro, MDc,e,*
Many case reports have indicated that myocarditis could be a prognostic factor for predicting morbidity and mortality among patients with COVID-19. In this study, using a
large database we examined the association between myocarditis among COVID-19 hospitalizations and in-hospital mortality and other adverse hospital outcomes. The present
study was a retrospective analysis of data collected in the California State Inpatient Database during 2020. All hospitalizations for COVID-19 were included in the analysis and
grouped into those with and without myocarditis. The outcomes were in-hospital mortality, cardiac arrest, cardiogenic shock, mechanical ventilation, and acute respiratory distress syndrome. Propensity score matching, followed by conditional logistic regression,
was performed to find the association between myocarditis and outcomes. Among 164,417
COVID-19 hospitalizations, 578 (0.4%) were with myocarditis. After propensity score
matching, the rate of in-hospital mortality was significantly higher among COVID-19 hospitalizations with myocarditis (30.0% vs 17.5%, p <0.001). Survival analysis with logrank test showed that 30-day survival rates were significantly lower among those with
myocarditis (39.5% vs 46.3%, p <0.001). Conditional logistic regression analysis showed
that the odds of cardiac arrest (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.16 to
3.14), cardiogenic shock (OR 4.13, 95% CI 2.14 to 7.99), mechanical ventilation (OR 3.30,
95% CI 2.47 to 4.41), and acute respiratory distress syndrome (OR 2.49, 95% CI 1.70 to
3.66) were significantly higher among those with myocarditis. Myocarditis was associated
with greater rates of in-hospital mortality and adverse hospital outcomes among patients
with COVID-19, and early suspicion is important for prompt diagnosis and management. © 2022 Published by Elsevier Inc. (Am J Cardiol 2022;183:109−114)

COVID-19, caused by SARS-CoV-2, has affected millions of people globally and continues to be a significant
cause of morbidity and mortality.1 COVID-19 typical
presents as interstitial pneumonia and can progress to lifethreatening complications such as disseminated intravascular coagulation, diffuse inflammatory syndrome, and multiorgan failure.2 Although initially described in some case
reports, it is now established that some patients develop cardiovascular complications, including myocarditis.3−5 Myocarditis in patients with COVID-19 is caused by both
inflammatory response against cardiac myocytes and
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suppression of protein synthesis within these cells.6 Myocarditis among patients with COVID-19 is often underdiagnosed because of unavailability or restricted use of
confirmatory tests such as cardiac magnetic resonance
imaging or endomyocardial biopsy, especially during peaks
of COVID-19 surges.7 Although many studies have stressed
the importance of myocarditis as a prognostic factor for predicting morbidity and mortality among patients with
COVID-19, there are few large-scale analyses.8−10 In this
study we examined, using a large database, the association
between myocarditis among COVID-19 hospitalizations
and in-hospital mortality and other adverse hospital outcomes.

Methods
The present study was a retrospective analysis of the
2020 California State Inpatient Database (SID). Every year,
SID collects discharge data from >90% of patients admitted
to community hospitals.11 The SID contains inpatient discharge information from participating states; information is
transformed into a uniform format for analyses. The SID
includes both clinical and nonclinical information on all
patients with various insurance coverage and on uninsured
www.ajconline.org
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patients. The SID contains variables such as primary and
secondary discharge diagnoses and procedures, admission
and discharge status, demographic characteristics, payment
source, hospitalization charges, and length of stay. Intermittent quality assurance procedures are performed to guarantee the validity of the database. We followed the STROBE
(STrengthening the Reporting of OBservational studies in
Epidemiology) guideline to ensure the quality of this
study.12
All patients ≥18 years of age who were hospitalized with
COVID-19 during 2020 in California were included in the
analysis. These hospitalizations were subsequently grouped
into those with and without myocarditis. We used the International Classification of Diseases, Tenth Revision (ICD10), Clinical Modification diagnosis and procedure codes to
identify hospitalizations and procedures (Supplementary
Table 1).
The primary outcome of the study was in-hospital mortality; secondary outcomes were cardiac arrest, cardiogenic
shock, mechanical ventilation, and acute respiratory distress
syndrome. Other variables included demographic characteristics, clinical risk profile, and Elixhauser co-morbidity
index score. We used ICD-10, Clinical Modification diagnosis and procedure codes to identify these variables (Supplementary Table 1).
Descriptive statistics were used to understand the differences in distribution of demographics and clinical characteristics between COVID-19 hospitalizations with and
without myocarditis. We conducted propensity score
matching to account and control for potential differences in
demographics and clinical profiles between hospitalizations
with and without myocarditis. We used a 1:1 greedy matching algorithm with a caliper size of 0.25 times the SD of the
logit of the propensity score to match the likelihood of having versus not having myocarditis. We set the standardized
mean differences in the distribution of covariates at <10%
to ensure adequate matching between the 2 groups.
We conducted survival analysis on unmatched and
matched data using Kaplan-Meier estimator to compare differences in 30-day mortality between COVID-19 hospitalizations with and without myocarditis. After adjusting for
covariates, multivariate conditional logistic regression analyses were used to find the associations between myocarditis
and cardiac arrest, cardiogenic shock, use of mechanical
ventilation, and acute respiratory distress syndrome.
To identify the potential confounding effects of coronary
artery disease, diabetes, and hypertension on the association
between myocarditis and in-hospital mortality, we conducted a subgroup analysis that included hospitalizations
with these potential confounding variables. For this group,
we compared the differences in 30-day mortality between
hospitalizations with and without myocarditis using propensity-score-matched data. Because missing data was <5%
for any variable, imputation was not conducted. To account
for misclassification, we considered the uncertainty in the
true values of bias parameters and simulated the effects of
adjusting for a range of sensitivity and specificity values.
Statistical significance was set at p <0.05, and all tests were
2-sided. All statistical analyses were conducted using SAS,
version 9.4 (SAS Inc., Cary, North Carolina).

Results
A total of 164,417 COVID-19 hospitalizations were
included in the analysis. Among these, 578 hospitalizations
(0.4%) had myocarditis. The majority of these hospitalizations occurred in patients aged ≥65 years, and most were in
men (Table 1). Hispanics constituted the majority of these
hospitalizations, followed by Whites, Asians, Pacific
Islanders, and Native Americans and Blacks. Medicare was

Table 1
Demographic and clinical characteristics of COVID-19 hospitalizations
with and without myocarditis
Characteristic

Myocarditis
No n = 163,893

P value

Yes n = 578

Age (years)
0.415
18-44
33616 (20.5%)
120 (20.8%)
45-64
57654 (35.2%)
196 (33.9%)
≥65
72623 (44.3%)
262 (45.3%)
Sex
<0.001
Male
88470 (54.0%)
356 (61.6%)
Female
75417 (46.0%)
222 (38.4%)
Race/ethnicity
0.264
White
41057 (25.4%)
135 (24.3%)
Black
10626 (6.6%)
38 (6.8%)
Hispanic
86668 (53.7%)
285 (51.4%)
Asian or Pacific Islander
14782 (9.2%)
65 (11.7%)
and Native American
Other
8313 (5.1%)
32 (5.8%)
Insurance
0.893
Medicare
69287 (42.3%)
250 (43.3%)
Medicaid
50285 (30.7%)
166 (28.7%)
Private insurance
36167 (22.1%)
132 (22.8%)
Uninsured
3060 (1.9%)
11 (1.9%)
Other
5019 (3.1%)
19 (3.3%)
Risk profile
Hypertension
96338 (58.8%)
344 (59.5%)
0.720
Diabetes mellitus
25734 (15.7%)
87 (15.1%)
0.668
Hyperlipidemia
60198 (36.7%)
215 (37.2%)
0.816
Obesity
42590 (26.0%)
155 (26.8%)
0.649
Atrial fibrillation
17965 (11.0%)
87 (15.1%)
0.001
Coagulation disorder
21584 (13.2%)
139 (24.0%)
<0.001
Peripheral vascular disease 10764 (6.6%)
32 (5.5%)
0.317
Liver disease
11052 (6.7%)
80 (13.8%)
<0.001
Chronic renal failure
33004 (20.1%)
140 (24.2%)
0.014
Stroke
8494 (5.2%)
41 (7.1%)
0.058
Congestive heart failure
23029 (14.1%)
188 (32.5%)
<0.001
Prior MI
5333 (3.3%)
39 (6.7%)
<0.001
Prior PCI
4166 (2.5%)
18 (3.1%)
0.383
Prior CABG
3721 (2.3%)
15 (2.6%)
0.600
Tobacco use
8545 (5.2%)
26 (4.5%)
0.439
Alcohol abuse
5095 (3.1%)
29 (5.0%)
0.007
Drug abuse
6450 (3.9%)
29 (5.0%)
0.182
Elixhauser comorbidity
<0.001
index
0
13770 (8.4%)
18 (3.1%)
1 or 2
51636 (31.5%)
130 (22.5%)
≥3
98487 (60.1%)
430 (74.4%)
Length of stay (days),
5.0 (3.0-10.0) 8.0 (4.0-16.0) <0.001
median (IQR)
CABG = coronary artery bypass grafting; IQR = interquartile range;
MI = myocardial infarction; PCI = percutaneous coronary intervention.
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Figure 1. Comparison of adverse hospital outcomes among COVID-19 hospitalizations with and without myocarditis.

the most common insurance coverage, followed by Medicaid and private insurance; some patients were uninsured.
The most common comorbidities were hypertension, hyperlipidemia, and congestive heart failure (CHF). Nearly 3/4
of these hospitalizations had Elixhauser co-morbidity index
score ≥3. There were significant differences in gender and
in Elixhauser comorbidity index scores between COVID-19
hospitalizations with and without myocarditis. The prevalence of comorbidities such as atrial fibrillation, coagulation
disorder, liver disease, chronic renal failure, CHF, previous
myocardial infarction, and alcohol abuse was significantly
higher among COVID-19 hospitalizations with myocarditis.
Hospital length of stay was significantly higher among
COVID-19 hospitalizations with myocarditis (Table 1).
Before propensity score matching, the rate of in-hospital
mortality was significantly higher among COVID-19 hospitalizations with myocarditis (Figure 1); it remained significant even after propensity score matching (30.0% vs
17.5%, p <0.001). Matching was successful in achieving
covariate balance between the groups with and without
myocarditis, as shown by a standardized difference of
<10% for all covariates after matching (Supplementary
Figure 1). Supporting this finding, survival analysis with
log-rank test also showed that 30-day survival rates were
significantly lower among those with myocarditis (39.5%
vs 46.3%, p <0.001) (Figure 2).
Subsequently, we conducted a subgroup analysis that
included all COVID-19 hospitalizations with coronary
artery disease, diabetes, and hypertension. In this subset,
survival analysis with log-rank test in a propensity-scorematched sample of 449 hospitalizations with myocarditis
and 449 without myocarditis showed that 30-day survival
rates were not significantly different between the 2 groups
(32.8% vs 35.4%, p = 0.267) (Figure 3).

Before propensity score matching, adverse hospital outcomes such as cardiac arrest, cardiogenic shock, mechanical ventilation, and acute respiratory distress syndrome
were significantly higher among COVID-19 hospitalizations with myocarditis (Figure 1). Conditional logistic
regression analysis showed that the odds of cardiac arrest,
cardiogenic shock, mechanical ventilation, and acute respiratory distress syndrome were significantly higher among
those with myocarditis (Table 2).
Trends in in-hospital mortality, cardiac arrest, cardiogenic shock, mechanical ventilation, and acute respiratory
distress syndrome among patients with myocarditis did not
change significantly across quarters of the year 2020 (Supplementary Figure 2).
Discussion
California ranks highest in the United States with respect
to total number of COVID-19 cases and COVID-19 deaths.
We found that in-hospital mortality, cardiac arrest, cardiogenic shock, mechanical ventilation, and acute respiratory
distress syndrome were significantly higher among
COVID-19 hospitalizations with myocarditis.
The prevalence of myocarditis among COVID-19 hospitalizations in our study was 0.4%. Studies have shown that
the prevalence of myocarditis among patients with COVID19 ranges from 0% to 15%.13−16 In a large-scale study
including 1,452,773 patients with COVID-19, the prevalence of myocarditis was 0.3%.17 Several other studies that
have reported higher mortality rates among patients with
COVID-19 with myocarditis also support our findings. For
example, a retrospective analysis of a large registry database showed that 30-day all-cause mortality was significantly higher among those with myocarditis (13.4% vs
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Figure 2. Kaplan−Meier curves comparing 30-day in-hospital mortality among COVID-19 hospitalizations with and without myocarditis. (A) Unmatched
hospitalizations; (B) propensity-score-matched hospitalizations.

4.2%, p <0.001).18 Similarly, fulminant myocarditis was
associated with greater mortality rates among patients with
COVID-19.19−21
It has been hypothesized that inflammatory cytokine
storm and direct action on myocytes through suppression of
protein synthesis could be responsible for myocardial
injury. Interleukin-6 constitutes the primary mediator of
cytokine storm and triggers proinflammatory responses
among immune cells such as T lymphocytes.6 This leads to
further activation of and cytokine release by immune cells,
leading to a negative spiral of immune-mediated myocardial injury. The special affinity of activated T lymphocytes
for myocardial cells is regulated through the interaction

between cardiac-synthesized hepatocyte growth factor and
hepatocyte growth factor receptor (c-Met), which is present
on naive T lymphocytes.22 Although many case studies
have associated COVID-19 with clinically suspected myocarditis,23−25 there have been very few cases in which it has
been confirmed histologically.26,27 Therefore, a general
consensus on the prognostic potential of myocarditis in
models predicting mortality among patients with COVID19 is yet to be established.
We found that adverse outcomes such as cardiac arrest,
cardiogenic shock, mechanical ventilation, and acute respiratory distress syndrome were higher in the myocarditis
group. These findings are not surprising because

Figure 3. Kaplan−Meier curves comparing 30-day in-hospital mortality among COVID-19 hospitalizations with and without myocarditis in the subgroup
with coronary artery disease, diabetes, and hypertension.
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Table 2
Association between myocarditis and hospital outcomes among COVID19 hospitalizations
Characteristic
Cardiac arrest
Cardiogenic shock
Mechanical ventilation
Acute respiratory distress syndrome

Odds ratio

P value

1.90 (1.16-3.14)
4.13 (2.14-7.99)
3.30 (2.47-4.41)
2.49 (1.70-3.66)

0.011
<0.001
<0.001
<0.001

Odds ratios were calculated using conditional logistic regression after
adjusting for age, sex race, insurance, hypertension, diabetes mellitus,
hyperlipidemia, obesity, atrial fibrillation, coagulation disorder, peripheral
vascular disease, liver disease, chronic renal failure, tobacco use, alcohol
abuse, drug abuse, stroke, congestive heart failure, prior MI, prior PCI,
and prior CABG. Complete model results are available from the authors
upon request.

complications such as CHF, ventricular arrhythmias, and
cardiogenic shock are common after acute myocarditis.28
However, it is concerning that these complications occur
even among healthy patients without a history of underlying
cardiac disease.29 It is also troubling that among patients
experiencing cardiac arrest, very few survive the transition
time to the hospital, and even fewer survive hospitalization
and management.30 Cardiogenic shock and cardiac arrest
among patients with COVID-19 are characterized by transient and global left ventricular dysfunction, even in the
absence of any pathology of the coronary vasculature.31 In
addition, these complications are precipitated by disruption
of the conduction system caused by altered intracellular signaling and ensuing interstitial edema and fibrotic changes.32
Higher rates of mechanical ventilation and acute respiratory
distress syndrome in this population are also obviously
because of the common mechanisms of tissue injury, such
as cytokine storm and T-cell activation.33 Given these
implications, it is important to be watchful for emerging
myocarditis to successfully identify and manage the complications during COVID-19 hospitalization.
Several new models have been developed for predicting
mortality among patients with COVID-19, and cardiac
injury is one of the important prognostic factors that indicate poor outcomes.34,35 However, some new models do
not include cardiac injury as a prognostic factor for predicting mortality in this population.36,37 In addition, conventional risk scores such as Confusion, Urea, Respiratory rate,
Blood pressure, and age ≥65 years; National Early Warning
Score 2; and Quick Sequential Organ Failure Assessment
do not accurately estimate the risk of adverse COVID-19
outcomes.38 These conventional risk scores do not include
cardiac injury as a prognostic factor. Similar to many other
investigators who have emphasized the importance of
including cardiac injury as a prognostic indicator for predicting mortality among patients with COVID-19, we
emphasize that inclusion of myocarditis would significantly
improve the accuracy of existing prognostic tools.8−10
Our study had some limitations. We used ICD-10 codes
for identifying hospitalizations, and there could be some
coding errors leading to misclassification bias. SID is an
administrative database, and therefore we could not ensure
whether these diagnoses were based on clinical findings or
on confirmatory tests such as cardiac magnetic resonance
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imaging or endomyocardial biopsy. In addition, SID does
not have data on troponin levels or on echocardiographic
evidence of left ventricular dysfunction to ensure that the
selected population indeed had clinical myocarditis. This
could have affected the accuracy of our estimates. SID does
not include laboratory results and medications. Availability
of such information could have significantly improved the
accuracy of our findings. Because vaccinations against
SARS-CoV-2 started to become available only during the
terminal stages of the study period, we did not have adequate information on vaccination status. The findings of our
study are not generalizable to the entire United States population because we used data from California, where there
were relatively very few patients with COVID-19 with
myocarditis.
Our study using a large administrative database found
that myocarditis was associated with greater rates of in-hospital mortality and adverse hospital outcomes among
patients with COVID-19. Hence, care providers should be
vigilant for emerging signs of myocarditis and attempt to
aggressively manage the condition. For better accuracy,
future prognostic models for estimating mortality and
adverse outcomes among patients with COVID-19 should
include myocarditis. Only through these efforts can we successfully manage myocarditis among patients with COVID19 and avert some of the fatal complications.
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